Tag Archive for: Pharmaceutical

Futura Medical plc – Appointment of Roy Davis as Non-Executive Director

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, today announces the appointment of Roy Davis as a Non-Executive Director with immediate effect. Read more…

European Commission revokes all centrally granted generic marketing permissions for dimethyl fumarate (“DMF”), including Dimethyl Fumarate Neuraxpharm

Decision is not due to any public health concerns regarding generic DMF products Neuraxpharm to swiftly contest this decision at the General Court of the European Union Barcelona and Düsseldorf – 20 December, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces […]

Futura expands partnership with M8 Pharmaceuticals for remainder of Central and South American region

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, is pleased to announce that M8 Pharmaceuticals, Inc (“M8”) has taken up its rights to extend its licensing agreement from Brazil and Mexico to market MED3000 in a further fourteen countries throughout the Central and South American region. Read more…

Futura Medical – Eroxon Awarded “New Product of the Year, Healthcare” by Boots

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, announces that Eroxon® has won the “New Product of the Year, Healthcare” category at the Boots Supplier Awards 2023, following its UK launch earlier this year. The award is further recognition for Futura’s breakthrough treatment for erectile dysfunction (“ED”) as it provides an […]

Futura Medical plc – Interim Results 2023

Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, is pleased to announce its unaudited interim results for the six months ended 30 June 2023 (“H1 2023”). MED3000, under the brand name Eroxon®, is the first pan-European clinically proven topical treatment for Erectile Dysfunction (“ED”) available without the need of a doctor’s prescription […]